Trial Radar AI
De klinische studie NCT07423143 (MISSION-O) voor menopauze, Opportunistic Salpingectomy is nog niet rekruterend. Bekijk de kaartweergave van de Klinische Studies Radar en de AI-ontdekkingstools voor alle details. Of stel hier een vraag.
Eén studie komt overeen met de filtercriteria
Kaartweergave
Terug naar zoekresultaten

Menopausal Impact of Opportunistic Salpingectomy for Ovarian Cancer Prevention (MISSION-O) 2.100 Preventie

Nog niet rekruterend
Informatie over klinische studies is voornamelijk in het Engels beschikbaar. Trial Radar AI kan echter helpen! Klik op 'Leg studie uit' om de informatie over de studie te bekijken en te bespreken in de taal van uw keuze.
De klinische studie NCT07423143 (MISSION-O) is een interventioneel studie bij menopauze, Opportunistic Salpingectomy met de status nog niet rekruterend. De inclusie van 2.100 deelnemers start op 1 maart 2026. De studie wordt geleid door de Universiteit van Umeå en de voltooiing is gepland op 1 december 2057. Laatste update op ClinicalTrials.gov: 20 februari 2026.
Beknopte samenvatting
The goal of this clinical trial is to find out whether removing the fallopian tubes at the time of hysterectomy leads to an earlier menopause. The study includes women under 55 years of age who previously underwent hysterectomy as participants in the HOPPSA trial, where they were randomly assigned to either removal of the fallopian tubes or no removal.

The main question is:

• Does removing the fallopian tubes at th...

Toon meer
Uitgebreide beschrijving
Opportunistic salpingectomy, defined as removal of the fallopian tubes during gynaecologic surgery performed for another indication, has been proposed as a strategy to reduce the risk of ovarian cancer. This approach is supported by accumulating evidence that many high-grade serous ovarian cancers originate in the distal fallopian tube. Although short-term surgical safety has been evaluated in randomized and observat...Toon meer
Officiële titel

Menopausal Impact of Opportunistic Salpingectomy for Ovarian Cancer Prevention

Aandoeningen
menopauzeOpportunistic Salpingectomy
Publicaties
Wetenschappelijke artikelen en onderzoekspapers gepubliceerd over deze klinische studie:
Andere studie-ID's
  • MISSION-O
  • MISSION-O-26
  • 2024-06333 (Ander subsidie-/financieringsnummer) (The Swedish Research Council)
  • RV-1004811 (Ander subsidie-/financieringsnummer) (Region Västerbotten)
  • Dnr. 2025-08086-01 (Overige identificatiecode) (The Swedish Ethical Review Authority)
NCT-ID
NCT07423143
Startdatum (Werkelijk)
2026-03
Laatste update geplaatst
2026-02-20
Verwachte einddatum
2057-12
Inschrijving (Geschat)
2.100
Studietype
Interventioneel
FASE
N.v.t.
Status
Nog niet rekruterend
Trefwoorden
opportunistic salpingectomy
hysterectomy
nested trial
randomised controlled trial
RCT
follicle-stimulating hormone
self-sampling
dried blood spot cards
Primaire doel
Behandeling
Toewijzing
Gerandomiseerd
Interventiemodel
Parallel
Blindering
Dubbelblind
Armen / Interventies
Deelnemersgroep/StudiearmInterventie/Behandeling
ExperimenteelOpportunistic salpingectomy
Salpingectomy at the time of hysterectomy for a benign reason
Opportunistic Salpingectomy
Removal of the fallopian tubes at the time of hysterectomy
Geen interventieNo salpingectomy
No salpingectomy at hysterectomy for a benign reason
N.v.t.
Primaire uitkomst
UitkomstmaatBeschrijving van de uitkomstmaatTijdsbestek
Age at menopause
Evaluated using serum follicle-stimulating hormone (FSH) levels analysed in self-sampled dried blood spots. Continuous outcome measured in years. Samples collected twice one year apart.
1 year
Secundaire uitkomst
UitkomstmaatBeschrijving van de uitkomstmaatTijdsbestek
Cardiovascular disease - CVD
Dichotomous outcome. Diagnosis will be classified according to ICD-10. Data from national health registers will be retrieved. The outcome will be further described according to types of cardiovascular disease, i.e. coronary heart disease and stroke, as well as age at CVD.
10-30 years after enrolment.
Mortality
Dichotomous outcome, the diagnosis is classified according to ICD-10. Data retrieved from the national Cause of Death Register. Mortality will be further described as all-cause mortality, and mortality due to cardio-vascular disease.
10-30 years after enrolment.
Deelname-assistent
Geschiktheidscriteria

Leeftijd van deelnemers
Volwassene, Oudere volwassene
Minimumleeftijd
20 Years
Geslachten die in aanmerking komen voor de studie
Vrouw
  • Having had hysterectomy for a benign indication
  • Less than 55 years at surgery
  • Was included in the ITT population of the HOPPSA register-based randomised controlled trial (R-RCT) of opportunistic salpingectomy
  • Informed consent

  • Ongoing systemic hormonal treatment using sex steroids
  • Bilateral oophorectomy
  • Cancer treatment affecting ovarian function
  • Other treatments with major effects on ovarian function
Umeå University logoUniversiteit van Umeå106 actieve klinische studies om te verkennen
Centraal Contactpersoon
Contact: Annika Idahl, MD, PhD, Professor, +46 90 786 73 18, [email protected]
Contact: Camilla Ersviken, Trial coordinator, [email protected]
1 Studielocaties in 1 landen
Umeå University, Umeå, 90346, Sweden
Sara Knip, MD, Contact, [email protected]
Marja-Liisa L Tafvelin, MSc, Contact, [email protected]